2380166-34-5
Chemical Structure
Zilebesiran sodium
Synonym(s): AD-85481 sodium; ALN-AGT sodium
- CAS No.: 2380166-34-5
- Formula:C532H678F7N177Na43O321P43S6
- Molecular Weight:16389 (free acid)
SMILES: [Zilebesiran (sodium)]
Biological Activity: Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zilebesiran sodium | Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023;389(3):228-238. doi:10.1056/NEJMoa2208391 [Content Brief]
- [2]. Dudzicz-Gojowy S, et al. Zilebesiran-Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension. J Clin Med. 2025;14(20):7365. Published 2025 Oct 17. [Content Brief]
Keywords
